Cargando…
Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide
The novel coronavirus SARS-CoV-2 has become a global health concern. The morbidity and mortality of the potentially lethal infection caused by this virus arise from the initial viral infection and the subsequent host inflammatory response. The latter may lead to excessive release of pro-inflammatory...
Autores principales: | Wang, Zhiyu, Wang, Yanfei, Vilekar, Prachi, Yang, Seung-Pil, Gupta, Mayuri, Oh, Myong In, Meek, Autumn, Doyle, Lisa, Villar, Laura, Brennecke, Anja, Liyanage, Imindu, Reed, Mark, Barden, Christopher, Weaver, Donald F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350920/ https://www.ncbi.nlm.nih.gov/pubmed/32704455 http://dx.doi.org/10.7717/peerj.9533 |
Ejemplares similares
-
Is Inhaled Furosemide a Potential Therapeutic for COVID-19?
por: Brennecke, Anja, et al.
Publicado: (2020) -
The hidden variables problem in Alzheimer's disease clinical trial design
por: Liyanage, S. Imindu, et al.
Publicado: (2018) -
Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis
por: Inokuchi, Ryota, et al.
Publicado: (2014) -
Effects of inhaled furosemide on dyspnea and pulmonary function in people with COPD: A literature review
por: Atwi, Zeina
Publicado: (2022) -
Diphenyldifluoroketone EF24 Suppresses Pro-inflammatory Interleukin-1 receptor 1 and Toll-like Receptor 4 in lipopolysaccharide-stimulated dendritic cells
por: Vilekar, Prachi, et al.
Publicado: (2015)